. 2022 Jun 30;30(11):510–518. doi: 10.1007/s12471-022-01702-x

Table 2.

Prevalence of pulmonary hypertension and comorbidity, raised laboratory values

	Total patient group	Pulmonary hypertension^a	No pulmonary hypertension^a	p-value
Pulmonary embolism	20/79 (25.3%)	4/23 (17.4%)	16/56 (28.6%)	0.796
Lung fibrosis/COPD	18/101 (17.8%)	7/30 (23.3%)	11/71 (15.5%)	0.398
Heart valve disease	6/101 (5.9%)	6/30 (20.0%)	0/71 (0%)	< 0.001
Heart failure	6/101 (5.9%)	3/30 (10.0%)	3/71 (4.2%)	0.358
Raised D‑dimer	38/65 (58.5%)	14/19 (73.7%)	24/46 (52.2%)	0.167
Raised CRP	71/78 (91.0%)	22/23 (95.7%)	49/55 (89.1%)	0.667
Raised ferritin	58/77 (75.3%)	15/23 (65.2%)	43/54 (79.6%)	0.248

COPD chronic obstructive pulmonary disease, CRP C-reactive protein

^aAs estimated by echocardiography